Contineum Therapeutics, Inc.
NASDAQTotal Valuation
Contineum Therapeutics, Inc. carries a market capitalization of 279.90M, placing it among publicly traded companies globally. Its enterprise value stands at 386.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 279.90M |
| Enterprise Value | 386.51M |
Share Statistics
Contineum Therapeutics, Inc. currently has 37.61M shares outstanding.
| Shares Outstanding | 37.61M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.57 |
| P/TBV Ratio | 2.57 |
| P/FCF Ratio | -10.43 |
| P/OCF Ratio | -10.34 |
Financial Position
Contineum Therapeutics, Inc. maintains a current ratio of 37.17, meaning it holds 37.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 37.17 |
| Quick Ratio | 36.25 |
| Debt / Equity | 2.74 |
| Debt / EBITDA | -0.10 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -28.01 |
| Return on Assets (ROA) | -26.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Contineum Therapeutics, Inc.'s stock has declined approximately -32.91253% over the past 52 weeks. The 50-day moving average sits at 13.83, while the 200-day moving average is 13.62.
| Beta (5Y) | N/A |
| 52-Week Price Change | -32.91253% |
| 50-Day Moving Average | 13.83 |
| 200-Day Moving Average | 13.62 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -66.00M, while operating income came in at -66.38M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -66.38M |
| Pretax Income | -57.56M |
| Net Income | -57.56M |
| EBITDA | -66.00M |
| EBIT | -66.38M |
| Earnings Per Share (EPS) | -1.72 |
Balance Sheet
Contineum Therapeutics, Inc. holds 236.55M in cash and equivalents against 6.57M in total debt, resulting in a net debt position of -14.71M. Total book value stands at 239.66M, with working capital of 236.05M providing operational flexibility.
| Cash & Cash Equivalents | 236.55M |
| Total Debt | 6.57M |
| Net Debt | -14.71M |
| Equity (Book Value) | 239.66M |
| Book Value Per Share | 6.37 |
| Working Capital | 236.05M |
Cash Flow
Contineum Therapeutics, Inc. produced -53.01M in operating cash flow over the past twelve months. After subtracting -458,000.00 in capital expenditures, free cash flow totaled -53.46M - equivalent to -1.60 per share.
| Operating Cash Flow | -53.01M |
| Capital Expenditures | -458,000.00 |
| Free Cash Flow | -53.46M |
| FCF Per Share | -1.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -18.48 |
| FCF Yield | -9.59 |
Scores
Contineum Therapeutics, Inc. posts an Altman Z-Score of 33.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 33.65 |